shigella sonnei strain wrss1 vaccine

WRSS1 is a live attenuated, oral vaccine candidate developed by the Walter Reed Army Institute of Research (WRAIR) to protect against *Shigella sonnei* infection. The vaccine strain is derived from the wild-type *S. sonnei* strain Mosely and is attenuated through the deletion of the *virG* (also known as *icsA*) gene, which is essential for intra- and intercellular bacterial spread, as well as the *sen* and *set* genes that encode Shigella enterotoxins 1 and 2. By mimicking a natural infection without causing clinical shigellosis, WRSS1 aims to elicit protective mucosal and systemic immune responses. Clinical development has included Phase 1 trials in both adult populations and pediatric cohorts in endemic regions like Bangladesh and Thailand, supported by organizations such as PATH and the U.S. Army Medical Research and Development Command.

Other names

WRSS1 vaccineWRSS-1 vaccineWRSS 1 vaccineLive attenuated Shigella sonnei vaccine WRSS1